ALK
ENSG00000171094
Target class
Kinase
Chromosome
2
Approved drugs
7
Clinical candidates (approved and in development)
11
- Approved drugs
- 7
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 11
- Chemical probe available
- Yes
- Target name
- ALK
- Gene name
- ALK receptor tyrosine kinase
- Gene symbol
- ALK
- Protein name
- ALK tyrosine kinase receptor (EC 2.7.10.1) (Anaplastic lymphoma kinase) (CD antigen CD246)
- CD246
- ALK1
- Gene biotype
- Protein coding
- Gene family
- Receptor tyrosine kinases|CD molecules
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 7
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 3.53
- Tissue specificity (Gini)
- 0.674
- Tissue specificity (tau)
- 0.891
- KEGG gene identifiers
- hsa:238
- Protein interaction confidence
- 0.863234
- Protein interaction partners
- 64
- R-HSA-201556
- R-HSA-9700645
- R-HSA-9717264
- R-HSA-9717301
- R-HSA-9717316
- R-HSA-9717319
- R-HSA-9717323
- R-HSA-9717326
- R-HSA-9717329
- R-HSA-9725370
- R-HSA-9851151
- End position
- 29921586
- Start position
- 29192774
- Chromosome
- 2
- Strand
- Reverse
- Cell membrane
- Single-pass type I membrane protein . Note=Membrane attachment is essential for promotion of neuron-like differentiation and cell proliferation arrest through specific activation of the MAP kinase pathway. .
- Plasma membrane
- PubMed 34819673
- PubMed 9174053
- PubMed 16317043
- Tissue specificity (tau)
- 0.891282
- Expression inequality (Gini)
- 0.67375
Expression in transcripts per million
- Pituitary
- 3.53
- Testis
- 3.08
- Brain - Hypothalamus
- 1.65
- Brain - Anterior cingulate cortex (BA24)
- 1.41
- Brain - Frontal Cortex (BA9)
- 1.37
Expression in transcripts per million
- Pituitary3.53
- Testis3.08
- Brain - Hypothalamus1.65
- Brain - Anterior cingulate cortex (BA24)1.41
- Brain - Frontal Cortex (BA9)1.37
- Colon - Sigmoid1.29
- Brain - Cortex1.2
- Brain - Amygdala0.92
- Brain - Nucleus accumbens (basal ganglia)0.9
- Brain - Substantia nigra0.73
- Esophagus - Muscularis0.72
- Esophagus - Gastroesophageal Junction0.67
- Brain - Caudate (basal ganglia)0.65
- Brain - Hippocampus0.64
- Brain - Spinal cord (cervical c-1)0.64
- Brain - Putamen (basal ganglia)0.61
- Nerve - Tibial0.47
- Colon - Transverse0.37
- Brain - Cerebellum0.28
- Brain - Cerebellar Hemisphere0.21
- Minor Salivary Gland0.18
- Small Intestine - Terminal Ileum0.18
- Cervix - Ectocervix0.16
- Breast - Mammary Tissue0.14
- Adipose - Subcutaneous0.13
And 29 more, listed on the interactive page.
- GO:0007165
- GO:0016310
- GO:0038083
- GO:0042981
- GO:0046777
- GO:0048666
- GO:0005886
- GO:0032991
- GO:0070062
- GO:0004713
- GO:0004714
- GO:0005515
- GO:0008201
- GO:0030298
- GO:0042802
Related records
Trials (450)
- -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
- A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors
- A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
- A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
- A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.
- A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects
- A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers
- A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
- A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
- A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
- A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
- A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
- A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics
- A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors
- A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
- A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
Drugs (22)
- Alectinib ALK tyrosine kinase receptor inhibitor
- Alectinib hydrochloride ALK tyrosine kinase receptor inhibitor
- ASP-3026 ALK tyrosine kinase receptor inhibitor
- Brigatinib ALK tyrosine kinase receptor inhibitor
- CEP-37440 ALK tyrosine kinase receptor inhibitor
- Ceritinib ALK tyrosine kinase receptor inhibitor
- Conteltinib ALK tyrosine kinase receptor inhibitor
- Crizotinib ALK tyrosine kinase receptor inhibitor
- Deulorlatinib ALK tyrosine kinase receptor inhibitor
- Ensartinib ALK tyrosine kinase receptor inhibitor
- Ensartinib hydrochloride ALK tyrosine kinase receptor inhibitor
- Entrectinib ALK tyrosine kinase receptor inhibitor
- Envonalkib
- Ficonalkib
- Gilteritinib
- Iruplinalkib
- Lorlatinib ALK tyrosine kinase receptor inhibitor
- Neladalkib
- PLB1003 ALK tyrosine kinase receptor inhibitor
- Repotrectinib